Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma

British Journal of Cancer

Volumn 107, Issue 7, 2012, Pages 1059-1068

  Delea, T E ^a   Khuu, A ^a   Heng, D Y ^b   Haas, T ^c   Soulieres D ^d  

^a POLICY ANALYSIS INC PAI   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

metastatic; progression; renal cell carcinoma; survival

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GAMMA INTERFERON; GEFITINIB; HISTAMINE; IMATINIB; INTERLEUKIN 2; ISOTRETINOIN; LAPATINIB; MEDROXYPROGESTERONE ACETATE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; VINBLASTINE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; DRUG DOSE COMPARISON; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; THERAPY EFFECT; TIME TO PROGRESSION SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866929052     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.367     Document Type: Article

References (69)

1. Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van PH, Fossa SD, de PL, Sylvester RJ (2005) Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23(18): 4172-4178
2. Amato RJ, Jac J, Hernandez-McClain J (2008) Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anticancer Drugs 19(5): 527-533
3. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5): 909-918
4. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M (2002) Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95(5): 1045-1050
5. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M (2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85(8): 1130-1136
6. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M (2004) Interleukin-2-and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22(7): 1188-1194
7. Atzpodien J, Kirchner H, Rebmann U, Soder M, Gertenbach U, Siebels M, Roigas J, Raschke R, Salm S, Schwindl B, Muller SC, Hauser S, Leiber C, Huland E, Heinzer H, Siemer S, Metzner B, Heynemann H, Fornara P, Reitz M (2006) Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 95(4): 463-469
8. Bowater RJ, Bridge LJ, Lilford RJ (2008) The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. Cancer Lett 262(1): 48-53
9. Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101(23): 1642-1649
10. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25(29): 4536-4541
11. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26(12): 1987-1992
12. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25(33): 5218-5224
13. Carroll KJ (2003) On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials 24(6): 682-701
14. Coppin C (2008) Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther 8(6): 907-919
15. Coppin C, Le L, Porzsolt F, Wilt T (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2: CD006017
16. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1: CD001425
17. Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM (2008) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26(22): 3791-3796
18. Donskov F, Middleton M, Fode K, Meldgaard P, Mansoor W, Lawrance J, Thatcher N, Nellemann H, von der Maase H (2005) Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br J Cancer 93(7): 757-762
19. Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ (2003) Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferongamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 20(3): 271-281
20. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109): 629-634
21. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, for the TARGET Study Group (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125-134
22. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, for the AVOREN Trial Investigators (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605): 2103-2111
23. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Negrier S, Huang X, Kim ST, Chen I, Motzer RJ (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26: 15
24. Finkelstein DM, Schoenfeld DA (2011) Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 trial by using the inverse probability of censoring weighted method. J Clin Oncol 29(9): 1093-1095
25. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125(7): 605-613
26. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375(9715): 641-648
27. Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI, Kollmannsberger C (2009a) A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115(4): 776-783
28. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009b) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34): 5794-5799
29. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22): 2271-2281
30. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL (2006) Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7(9): 741-746
31. Knox JJ (2008) Progression-free survival as endpoint in metastatic RCC? Lancet 372(9637): 427-429
32. Korhonen P, Malangone E (2010) Overall survival (OS) of mRCC patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: two analyses from the RECORD-1 trial. J Clin Oncol 28(Suppl): 15S (abstract 4595)
33. Korhonen P, Malangone E, Sherman S, Casciano R, Motzer RJ, Baladi J, Haas T, Zuber E, Hollaender N, Lebwohl DE (2011) Overall survival (OS) of mRCC patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: two analyses from the RECORD-1 trial. In: 10th International Kidney Cancer Symposium. 14-15 October 2011: Kidney Cancer Association. Chicago, IL, USA.
34. Kruit WH, Goey SH, Lamers CH, Gratama JW, Visser B, Schmitz PI, Eggermont AM, Bolhuis RL, Stoter G (1997) High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokineactivated killer cells in patients with metastatic renal cell cancer. J Immunother 20(4): 312-320
35. Louvet C, de GA, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M (2001) Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91(11): 2033-2038
36. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CPG, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1): 133-141
37. Medical Research Council Renal Center Collaborators (1999) Interferonalpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353(9146): 14-17
38. Molina AM, Motzer RJ (2008) Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer 6(Suppl 1): S7-S3
39. Morden JP, Lambert PC, Latimer N, Abrams KR, Wailoo AJ (2011) Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Med Res Methodol 11: 4
40. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18): 4256-4265
41. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, for the RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449-456
42. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized Phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30(12): 1371-1377
43. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22): 3584-3590
44. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124
45. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18(16): 2972-2980
46. Negrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, Viens P, Gomez F (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 18(24): 4009-4015
47. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T, for the Groupe Francais d'Immunotherapie (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338(18): 1272-1278
48. Negrier S, Perol D, Ravaud A, Bay JO, Oudard S, Chabaud S, Fargeot P, Delva R, Deplanque G, Gravis G, Escudier B (2008) Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res 14(18): 5907-5912
49. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B, for the French Immunotherapy Intergroup (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110(11): 2468-2477
50. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17(9): 2859-2867
51. Rimawi M, Hilsenbeck SG (2012) Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol 30(4): 453-458
52. Rini B, Wilding GT, Hudes G (2007) Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25(18S, 20 June Supplement): 5032
53. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13): 2137-2143
54. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renalcell cancer: a phase II study. Lancet Oncol 8(11): 975-984
55. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23(24): 5474-5483
56. Saad ED, Buyse M (2012) Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 30(15): 1750-1754
57. Sargent DJ, Hayes DF (2008) Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol 26(12): 1922-1923
58. Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M, Cuzick J (2008) Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 99(10): 1572-1578
59. Soulieres D (2009) Review of guidelines on the treatment of metastatic renal cell carcinoma. Curr Oncol 16(Suppl 1): S67-S70
60. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010a) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6): 1061-1068
61. Sternberg CN, Hawkins RE, Szczylik C, Davis ID, Wagstaff J, McCann L, Chen M, Rubin SD (2010b) Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (MRCC): final overall survival (OS) results. Annals Oncol 21(Suppl 8): viii1-viii12
62. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, Pandite L, Chen M, McCann L, Hawkins R (2009) A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Presentation available at http://www.asco.org/ ascov2/Meetings/Abstracts?&vmview= abst-detail-view&confID= 65&abstractID=30883 (Accessed 16 April, 2012). J Clin Oncol 27: (15s (suppl; abstract 5021))
63. Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25: 4562-4568
64. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C (2006) Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9): 2254-2261
65. Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K (2010) Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 14(2): 1-184, iii-iv
66. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16
67. Warren M, Venner PM, North S, Cheng T, Venner C, Ghosh S, Venner AA, Finch D (2009) A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 3(4): 281-289
68. Wiederkehr D, Howe CJ, Casciano R, Motzer R, Zheng J, Baladi JF (2011) Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analyses from the RECORD phase 3 trial. Presented at the Joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), 20-24 September, 2009, Berlin, Germany
69. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5): 427-434